An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers

To determine bioequivalence of a generic 10 mg montelukast tablet formulation. A 2-period, 2- sequence crossover study was designed. It included 28 healthy subjects, each subject received a single dose of the randomly assigned formulation with 240 ml water after 10-hr fasting, and 14 blood samples...

Full description

Bibliographic Details
Main Authors: Chaveewan Ratanajamit, Bodin Khwannimit, Kiticha Chotephinyononte
Format: Article
Language:English
Published: Prince of Songkla University 2017-06-01
Series:Songklanakarin Journal of Science and Technology (SJST)
Subjects:
Online Access:http://rdo.psu.ac.th/sjstweb/journal/39-3/39-3-7.pdf
_version_ 1818513779682443264
author Chaveewan Ratanajamit
Bodin Khwannimit
Kiticha Chotephinyononte
author_facet Chaveewan Ratanajamit
Bodin Khwannimit
Kiticha Chotephinyononte
author_sort Chaveewan Ratanajamit
collection DOAJ
description To determine bioequivalence of a generic 10 mg montelukast tablet formulation. A 2-period, 2- sequence crossover study was designed. It included 28 healthy subjects, each subject received a single dose of the randomly assigned formulation with 240 ml water after 10-hr fasting, and 14 blood samples (6 mL each) were drawn at predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 7, 10, 12 and 24 hr post-dose. The procedure was repeated after a 7-day washout period. Plasma samples were stored at -20°C until analysed using LC-MS/MS, LLOQ 5 ng/mL. The mean ± SD for the test and the reference were: Cmax 568±185 and 570±205 ng/mL; and AUC0-” 3864±1228 and 4022±1331 ng.hr/mL, respectively. The log-transformed ratios (90% CI) were: Cmax : 99.64% (92.80% - 109.66%); and AUC0- : 99.79 (92.25% - 102.37%). The two formulations were bioequivalent as the 90% CI for the log-transformed ratios for the mean Cmax , and AUC0- were within the 80-125%.
first_indexed 2024-12-11T00:06:16Z
format Article
id doaj.art-9de300e4e7794d748ee01b6bda53515d
institution Directory Open Access Journal
issn 0125-3395
language English
last_indexed 2024-12-11T00:06:16Z
publishDate 2017-06-01
publisher Prince of Songkla University
record_format Article
series Songklanakarin Journal of Science and Technology (SJST)
spelling doaj.art-9de300e4e7794d748ee01b6bda53515d2022-12-22T01:28:19ZengPrince of Songkla UniversitySongklanakarin Journal of Science and Technology (SJST)0125-33952017-06-0139333534010.14456/sjst-psu.2017.36An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteersChaveewan Ratanajamit0Bodin Khwannimit1Kiticha Chotephinyononte2Clinical and Pharmacological Research Unit, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hat Yai, Songkhla, 90110 ThailandDepartment of Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110 ThailandAll Research Co., Ltd., 23, Sukhumvit Road 62, Bangchark, Phra Khanong, Bangkok, 10260 ThailandTo determine bioequivalence of a generic 10 mg montelukast tablet formulation. A 2-period, 2- sequence crossover study was designed. It included 28 healthy subjects, each subject received a single dose of the randomly assigned formulation with 240 ml water after 10-hr fasting, and 14 blood samples (6 mL each) were drawn at predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 7, 10, 12 and 24 hr post-dose. The procedure was repeated after a 7-day washout period. Plasma samples were stored at -20°C until analysed using LC-MS/MS, LLOQ 5 ng/mL. The mean ± SD for the test and the reference were: Cmax 568±185 and 570±205 ng/mL; and AUC0-” 3864±1228 and 4022±1331 ng.hr/mL, respectively. The log-transformed ratios (90% CI) were: Cmax : 99.64% (92.80% - 109.66%); and AUC0- : 99.79 (92.25% - 102.37%). The two formulations were bioequivalent as the 90% CI for the log-transformed ratios for the mean Cmax , and AUC0- were within the 80-125%.http://rdo.psu.ac.th/sjstweb/journal/39-3/39-3-7.pdfbioequivalencemontelukastpharmacokineticsLC/MS/MSallergic rhinitisasthma
spellingShingle Chaveewan Ratanajamit
Bodin Khwannimit
Kiticha Chotephinyononte
An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers
Songklanakarin Journal of Science and Technology (SJST)
bioequivalence
montelukast
pharmacokinetics
LC/MS/MS
allergic rhinitis
asthma
title An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers
title_full An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers
title_fullStr An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers
title_full_unstemmed An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers
title_short An open-label, randomized, cross-over bioequivalence study of montelukast 10 mg tablets in healthy Thai volunteers
title_sort open label randomized cross over bioequivalence study of montelukast 10 mg tablets in healthy thai volunteers
topic bioequivalence
montelukast
pharmacokinetics
LC/MS/MS
allergic rhinitis
asthma
url http://rdo.psu.ac.th/sjstweb/journal/39-3/39-3-7.pdf
work_keys_str_mv AT chaveewanratanajamit anopenlabelrandomizedcrossoverbioequivalencestudyofmontelukast10mgtabletsinhealthythaivolunteers
AT bodinkhwannimit anopenlabelrandomizedcrossoverbioequivalencestudyofmontelukast10mgtabletsinhealthythaivolunteers
AT kitichachotephinyononte anopenlabelrandomizedcrossoverbioequivalencestudyofmontelukast10mgtabletsinhealthythaivolunteers
AT chaveewanratanajamit openlabelrandomizedcrossoverbioequivalencestudyofmontelukast10mgtabletsinhealthythaivolunteers
AT bodinkhwannimit openlabelrandomizedcrossoverbioequivalencestudyofmontelukast10mgtabletsinhealthythaivolunteers
AT kitichachotephinyononte openlabelrandomizedcrossoverbioequivalencestudyofmontelukast10mgtabletsinhealthythaivolunteers